INTEGRA LIFESCIENCES HOLDINGS CORP Form 8-K August 03, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2015

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

(Exact name of Registrant as specified in its charter)

Delaware (State or other jurisdiction of 0-26224 (Commission 51-0317849 (I.R.S. Employer

incorporation or organization)

File Number) 311 Enterprise Drive **Identification No.)**

Edgar Filing: INTEGRA LIFESCIENCES HOLDINGS CORP - Form 8-K

Plainsboro, NJ 08536

(Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code: (609) 275-0500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On August 3, 2015, Integra LifeSciences Holdings Corporation (the Company) announced the commencement of an underwritten public offering of \$200,000,000 of shares of its common stock. The Company expects to grant the underwriters of the offering an option to purchase up to \$30,000,000 of additional shares of its common stock. A copy of the press release is attached as Exhibit 99.1 to this report, and is incorporated herein by reference.

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

99.1 Press Release, dated August 3, 2015, issued by Integra LifeSciences Holdings Corporation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: August 3, 2015

- By: /s/ Glenn G. Coleman Glenn G. Coleman
- Title: Corporate Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit

No.

Description

99.1 Press Release, dated August 3, 2015, issued by Integra LifeSciences Holdings Corporation.